ADx logo

research & development

Pipeline

ADx is developing a broad spectrum of biomarkers applicable in neurodegenerative diseases ranging from Alzheimer’s disease to traumatic brain injury to Parkinson’s disease. All markers are detected in the cerebrospinal fluid (CSF) unless noted otherwise.

Discovery & concept Materials Feasibility assay design Prototype Analytical qualification Analytical validation + clinical qualification RUO / CE / SFDA
ALZHEIMER MARKERS
Aβ 1-40, Aβ 1-42, Aβ 1-38
Aβ 1-40, Aβ 1-42, Aβ 1-38 (Blood)
Total tau
P-tau
Neurogranin
BACE 1
SNAP 25
APO E4 (Blood)
PARKINSON MARKERS
α-SYNUCLEIN
TRAUMATIC BRAIN INJURY MARKERS
Total tau (Blood)
ALS MARKERS
Neurofilament


Collaborations

Some of the ADx markers were developed and commercialized in collaboration with our partners. The new generation of Alzheimer's disease diagnostics, using Aβ 1-40, Aβ 1-42 and total tau, is now available through our partner EuroImmun. For the development of a total tau blood test, we are collaborating with IVD enterprise Quanterix.

 

Other programs enjoy the financial support from various instances who believe in the know-how and technology of ADx. The development of α-synuclein as a marker for Parkinson's disease is supported by the Michael J. Fox Foundation while our advances with the marker neurogranin are supported by the IWT/VLAIO.